<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501550</url>
  </required_header>
  <id_info>
    <org_study_id>CDI-31244-P2-001</org_study_id>
    <nct_id>NCT03501550</nct_id>
  </id_info>
  <brief_title>Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)</brief_title>
  <official_title>An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cocrystal Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cocrystal Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir
      followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic
      hepatitis C (HCV) genotype 1 (GT1) infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is open label and has one treatment group. Eligible HCV GT1 subjects will self
      administer orally 400 mg of CDI-31244 and fixed dose combination of sofosbuvir and
      velpatasvir for 14 days. After 14 days the subjects will continue the treatment for another 4
      weeks on the fixed dose combination sofosbuvir and velpatasvir. The subjects will be followed
      up until 24 weeks after the last dose of sofosbuvir and velpatasvir to determine if sustained
      virologic response at 12 (SVR12) and 24 (SVR24) weeks after treatment have been achieved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">January 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Day 1 to Day 72</time_frame>
    <description>The safety and the tolerability of CDI-31244 in combination with SOF/VEL through number of AEs observed in participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 12 weeks</measure>
    <time_frame>post-treatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 24 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>post-treatment Week 24</time_frame>
    <description>SVR 24 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 24 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 in combination with SOF/VEL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDI-31244</intervention_name>
    <description>investigational drug</description>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <other_name>CDI-31244 (non-nucleoside inhibitor or NNI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/VEL</intervention_name>
    <description>sofosbuvir and velpatasvir fixed dose combination</description>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Documented chronic HCV GT 1 infection; Serum HCV RNA &gt;1,000 IU/mL during screening; Absence
        of advanced fibrosis or cirrhosis

        Key Exclusion Criteria:

        Nursing or pregnant women; Active hepatitis B infection; Human immunodeficiency virus (HIV)
        infection; History of use of any HCV direct-acting antiviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Chua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Virology, University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Human Virology University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>GT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

